Friedreich's Ataxia Efficacy Studies

Friedreich’s Ataxia (FRDA) is an autosomal recessive neurodegenerative disorder that is predominantly caused by a homozygous GAA repeat expansion mutation within intron 1 of the Frataxin (FXN) gene. This inherited disease causes nervous system damage and movement problems. To date, there is no cure or effective treatment for FRDA.

Request a Quote

Please fill out the web form below.


If you need further assistance please contact us at any time by calling 1-800-422-6423 (toll free to the USA, Canada and Puerto Rico) or 1-207-288-5845 (from any location). Our team is standing by 8:00 a.m. – 8:00 p.m. EST.

* Designates required information

Corporate/institutional email addresses only

Need assistance with this form?

FRDA Efficacy Studies

We provide proof of concept studies and/or drug efficacy studies in Friedreich’s Ataxia models including services such as clinical observations, body weights, tissue and/or blood collection, and molecular analyses (e.g. ELISA or western blotting) for evaluation of FXN expression levels in the most published models of FRDA:

  • B6.Cg-Fxntm1.1Pand Fxntm1Mkn/J (012329)
  • B6.Cg-Tg(FXN)1Sars Fxntm1Mkn/J (008586
  • STOCK Tg(FXN*)1Sars Fxntm1Mkn/J (018299)
    • The hybrid FVB;B6 genetic background version of strain 008586, offering the productive advantage of larger litters for easier colony maintenance compared to the C57BL/6-congenic.